Biochemical and vascular aspects of pediatric chronic fatigue syndrome.
Kennedy, Gwen, Khan, Faisel, Hill, Alexander et al. · Archives of pediatrics & adolescent medicine · 2010 · DOI
Quick Summary
This study compared 25 children with ME/CFS to 23 healthy children to understand what happens in their bodies at a chemical and blood vessel level. The researchers found that children with ME/CFS had signs of increased oxidative stress (cellular damage from harmful molecules) and more dying white blood cells, similar to what has been seen in adults with ME/CFS. However, unlike adults, the children's blood vessel stiffness appeared normal.
Why It Matters
This study provides biological evidence that ME/CFS in children involves real, measurable changes in cellular metabolism and immune function—not psychosomatic illness. Understanding these biochemical signatures in pediatric populations helps establish a biological foundation for the disease and may eventually guide diagnostic tests and treatment targets specific to young patients.
Observed Findings
Children with ME/CFS had significantly higher isoprostane levels (252.30 vs 215.60 pg/mL, P=.007), indicating increased oxidative stress.
Vitamin C levels were lower in children with ME/CFS (0.84 vs 1.15 mg/dL, P<.001).
Vitamin E levels were reduced in the ME/CFS group (8.72 vs 10.94 microg/mL, P=.01).
White blood cell apoptosis (cell death) was elevated: neutrophils 53.7% vs 35.7% (P=.005) and lymphocytes 40.1% vs 24.6% (P=.009).
Arterial stiffness measures did not differ significantly between groups, contrary to findings in adults with ME/CFS.
Inferred Conclusions
Pediatric ME/CFS shares some biochemical abnormalities with adult ME/CFS, particularly increased oxidative stress and white blood cell apoptosis, suggesting overlapping biological mechanisms across age groups.
The correlation between arterial stiffness measures and cholesterol levels appears specific to ME/CFS patients, suggesting altered vascular-metabolic relationships in the disease.
Unlike adults with ME/CFS, children with the condition do not yet show significant arterial stiffness despite having other biomarkers of disease.
Remaining Questions
Do the observed biochemical abnormalities improve, persist, or worsen as children with ME/CFS age, and do they predict development of arterial stiffness later in life?
What This Study Does Not Prove
This study does not prove that oxidative stress *causes* ME/CFS symptoms; it only shows an association. The cross-sectional design cannot establish whether these biochemical changes precede illness onset, develop as a consequence of illness, or both. Results are limited to a relatively small sample and cannot be generalized to all ME/CFS patients without replication in larger, more diverse populations.
What causes the increased oxidative stress and white blood cell apoptosis, and can these processes be reversed or modified by treatment?
Why do arterial stiffness patterns differ between pediatric and adult ME/CFS patients, and what does this reveal about disease progression or heterogeneity?
Do these biomarkers correlate with symptom severity or specific clinical presentations, and could they eventually be used for diagnosis or prognosis?